The impact of regular enteral feeding via jejunostomy during neo-adjuvant chemotherapy on body composition in patients with oesophageal cancer
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Nutrition"
DOI: 10.1016/j.clnu.2018.06.1338
Abstract: BACKGROUND Malnourishment and sarcopenia are well documented phenomena in oesophageal cancer. Patients undergoing neo-adjuvant chemotherapy prior to oesophagectomy have complex nutritional needs. AIM To examine the effect of regular nutritional support via feeding jejunostomy on… read more here.
Keywords: chemotherapy; adjuvant chemotherapy; body composition; jejunostomy ... See more keywords
OP53 Health Technology Assessment Acceptability Of Innovative Survival Metrics In Oncology
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s026646231900117x
Abstract: Introduction Most new oncology therapies are studied in the advanced/metastatic setting. However, there is an increasing focus on earlier stage disease. Nevertheless, measuring Overall Survival (OS) in neo-/adjuvant therapy trials can be very challenging due… read more here.
Keywords: technology assessment; survival metrics; neo adjuvant; health ... See more keywords
A phase II study on the neo-adjuvant combination of pazopanib and radiotherapy in patients with high-risk, localized soft tissue sarcoma
Sign Up to like & getrecommendations! Published in 2021 at "Acta Oncologica"
DOI: 10.1080/0284186x.2021.1971294
Abstract: Abstract Purpose A prior phase I study showed that the neo-adjuvant combination of pazopanib and radiotherapy was well tolerated, and induced promising pathological responses in soft-tissue sarcoma patients. Results of the subsequent prospective, multicenter phase… read more here.
Keywords: tissue sarcoma; combination; pazopanib; neo adjuvant ... See more keywords
Oncological and obstetrical outcomes after neo-adjuvant chemotherapy followed by fertility-sparing surgery in patients with cervical cancer ≥2 cm
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2020-002076
Abstract: Objective There is significant debate between up-front radical trachelectomy versus neo-adjuvant chemotherapy before fertility-sparing surgery in patients with tumors ≥2 cm. The aim of this study was to report on the oncological and obstetrical outcome of… read more here.
Keywords: chemotherapy; surgery; adjuvant chemotherapy; fertility sparing ... See more keywords
Fertility-sparing surgery after neo-adjuvant chemotherapy in women with cervical cancer larger than 4 cm: a systematic review
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2021-003297
Abstract: Objective The objective of this systematic review was to assess the oncologic and fertility outcomes of patients with cervix-confined cancer >4 cm who underwent neo-adjuvant chemotherapy followed by fertility-sparing surgery. Methods This study was registered… read more here.
Keywords: neo adjuvant; surgery; fertility sparing; fertility ... See more keywords
Abstract 1678: Overcoming treatment resistance in advanced bladder cancers using a neo-adjuvant combination with a natural product analog
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1678
Abstract: Urinary bladder cancer (BC) is a common cancer worldwide, with approximately 573,278 new cases and 212,536 deaths arising annually. Tumors detected beyond the transitional zone of the bladder (advanced BC) account for most deaths. In… read more here.
Keywords: bladder; gem; neo adjuvant; resistance ... See more keywords
CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
Sign Up to like & getrecommendations! Published in 2018 at "BMC Cancer"
DOI: 10.1186/s12885-018-4770-2
Abstract: BackgroundAlthough radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor. Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy, postoperative chemoradiotherapy and postoperative chemotherapy. However, these regimens… read more here.
Keywords: chemotherapy; resectable gastric; chemoradiotherapy; neo adjuvant ... See more keywords
Neutropenic complications with neo/adjuvant adriamycin and cyclophosphamide in early stage breast cancer patients: A prospective study at the McGill University health center.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e12127
Abstract: e12127Background: We prospectively investigated the incidence of neutropenic complications (NC) with neo/adjuvant AC (doxorubicin and cyclophosphamide) chemotherapy (CTX) among early-stage breast cancer (ESBC) patients. NC was defined as febrile neutropenia (FN), dose delay/reduction or need… read more here.
Keywords: stage breast; neo adjuvant; complications neo; center ... See more keywords
An open-label, phase Ib study of NEO-PV-01 + adjuvant with nivolumab in patients with melanoma, non-small cell lung carcinoma, or transitional cell carcinoma of the bladder.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps3116
Abstract: TPS3116Background: Cancer cells contain unique DNA mutations that result in altered amino acid sequences known as neoantigens. Growing evidence supports a central role for neoantigens as targets fo... read more here.
Keywords: label phase; study neo; neo adjuvant; open label ... See more keywords
Patient-reported outcomes of patients treated with (neo)adjuvant immune checkpoint combination therapy in high-risk stage III macroscopic melanoma: A matched cohort study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.9588
Abstract: 9588 Background: Results from the phase 1b (OpACIN) study comparing neoadjuvant to adjuvant ipilimumab (3mg/kg) plus nivolumab (1mg/kg) demonstrated a high clinical activity of neoadjuvant treatment in high-risk melanoma. However, the toxicity was high, with… read more here.
Keywords: high risk; reported outcomes; adjuvant immune; treated neo ... See more keywords
Haematological biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA non-small cell lung cancer (NSCLC) patients.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e20026
Abstract: e20026 Background: PD1/PDL1 treatments have become the main therapy in advanced stages of NSCLC due to its significant increase in overall survival (OS), but recently, combination with chemotherapy in locally advanced stages is showing promising… read more here.
Keywords: chemo immunotherapy; treatment; response; neo adjuvant ... See more keywords